CTX131
Cell therapy
Evidence outlook · program status
Discontinued (2025-11-10), as a strategic decision by the sponsor
CRISPR Therapeutics redirected resources away from CTX131 (Q3 2025 results). The trials below are preserved as the program's evidence history; no evidence signal is assigned to a program the sponsor has stopped.
How the evidence outlook works ↗
Featured trials
The studies most instrumental to this drug's clinical progression, individually graded on design and result. The complete registry, including every study not featured here, is listed below.
| Trial | Phase | Endpoint | Key result | Signal | Source |
|---|---|---|---|---|---|
NCT05795595 NCT05795595 · Clear Cell Renal Cell Carcinoma Registry: NCT05795595 | 1 | Phase 1 (Dose Escalation): Incidence of adverse events (From CTX131 infusion up to 28 days post-infusion); Phase 2 (Cohort Expansion): Objective response rate (ORR) (From CTX131 infusion up to 60 months post-infusion) 2025-09-18 | Results not posted; external-source review pending | not yet graded | link ↗ |
All registered studies
Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase.
Phase 1 (2)
What this study did
What this study did
Competitive landscape
Other CD70 drugs
2 other tracked programmes target this mechanism, 2 of them ahead of this one.
This drug's own stage for Clear Cell Renal Cell Carcinoma: Discontinued. Competitors below are sorted furthest-along first.
| Drug | Stage | Modality | Mechanism | Evidence signal | Reported efficacygraded featured trials | |
|---|---|---|---|---|---|---|
| CTX131: this drug | Discontinued | Cell therapy | CD70 | not yet graded | No reviewed efficacy summary in this indication | |
| Cabozantinib | Approved | Small molecule | MET / VEGFR / AXL / RET (multi-kinase) | Partial signal | No reviewed efficacy summary in this indication | |
| Casdatifan | Phase 3 | Small molecule | HIF-2alpha | not yet graded | No reviewed efficacy summary in this indication | |
| Cusatuzumab | Phase 2(overall) | Monoclonal antibody | CD70 | Weak signal(overall) | No reviewed efficacy summary in this indication | |
| Zanzalintinib | Phase 2 | Small molecule | VEGFR2; MET; AXL; MER; TYRO3 | not yet graded | No reviewed efficacy summary in this indication | |
| GI-101A | Phase 1/2 | Protein / enzyme therapeutic | CTLA-4 / IL-2Rβγ | not yet graded | No reviewed efficacy summary in this indication | |
| Darlifarnib | Phase 1 | Small molecule | Farnesyltransferase | not yet graded | No reviewed efficacy summary in this indication | |
| HS-IT101 | Phase 1 | Cell therapy | Autologous tumor neoantigens (polyclonal, patient-specific) | not yet graded | No reviewed efficacy summary in this indication | |
| XmAb819 | Phase 1 | Multispecific antibody | ENPP3 x CD3 | not yet graded | No reviewed efficacy summary in this indication | |
| PF-08046040 | —(overall) | Undisclosed | CD70, CD70, CD70, CD70, CD70, CD70, CD70, CD70, CD70, CD70, CD70, CD70, CD70, CD70, CD70, CD70 | not yet graded(overall) | No reviewed efficacy summary in this indication |
Upcoming events
No upcoming readouts on record for this asset.